Anti-Dabigatran Etexilate Antibody (SAA0560)

Catalog No.

RGK09701

Species reactivity

General

Host species

Mouse

Isotype

IgG2a

Clonality

Monoclonal

Target

dabigatran etexilate, Dabigatran etexilate mesylate, Dabigatran etexilate methanesulfonate

Concentration

1 mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>95% as determined by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Applications

ELISA

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

Clone ID

SAA0560

DOAC-Stop™ reverses the anticoagulant effect of asundexian and milvexian., PMID:40484204

Systematic Literature Review of DOACs as Treatment for Confirmed or Suspected Heparin-Induced Thrombocytopenia (HIT)., PMID:40411430

Intravenous thrombolysis for patients with acute ischemic stroke while receiving a direct oral anticoagulant: A systematic review and meta-analysis., PMID:39831680

Coagulation in familial hypercholesterolemic patients: effect of current hypolipidemic treatment and anticoagulants., PMID:39751820

Comparing the Effect of DOAC-Stop® and DOAC-Remove® on Apixaban, Rivaroxaban and Dabigatran Prior to Thrombophilia and Lupus Testing., PMID:39534247

Thrombolysis After Dabigatran Reversal for Acute Ischemic Stroke: A National Registry-Based Study and Meta-Analysis., PMID:39255429

Reversal of direct oral anticoagulants: guidance from the SSC of the ISTH., PMID:39029742

Anticoagulation reversal (vitamin K, prothrombin complex concentrates, idarucizumab, andexanet-α, protamine)., PMID:38926082

[Overdosing of direct oral anticoagulants]., PMID:38916655

Idarucizumab in dabigatran-treated patients with acute stroke: a review and clinical update., PMID:38817549

Is there a role for the laboratory monitoring in the management of specific antidotes of direct oral anticoagulants?, PMID:38626592

Disentangling the riddle of systemic lupus erythematosus with antiphospholipid syndrome: blood transcriptome analysis reveals a less-pronounced IFN-signature and distinct molecular profiles in venous versus arterial events., PMID:38609158

Drug-Drug Interactions of FXI Inhibitors: Clinical Relevance., PMID:38534886

Latest advances in the reversal strategies for direct oral anticoagulants., PMID:38350629

Dabigatran pharmacokinetic-pharmacodynamic in sheep: Informing dose for anticoagulation during cardiopulmonary bypass., PMID:38171494

Reversing dabigatran effect with idarucizumab to enable intravenous thrombolysis in patients with acute ischaemic stroke - a single centre experience., PMID:37955597

Idarucizumab for Emergency Reversal of the Anticoagulant Effects of Dabigatran: Final Results of a Japanese Postmarketing Surveillance Study., PMID:37845427

[Basics for the Use of Andexanet]., PMID:37813368

Laboratory-guided repeat dosing of idarucizumab for dabigatran reversal., PMID:37668187

The effects of coagulation factors and their inhibitors on proliferation and migration in colorectal cancer., PMID:37455592

Idarucizumab for dabigatran reversal: A systematic review and meta-analysis of indications and outcomes., PMID:37267671

News at XI: moving beyond factor Xa inhibitors., PMID:37116752

Pharmaceutical treatment of bone loss: From animal models and drug development to future treatment strategies., PMID:36933702

Supratherapeutic dabigatran: a cause of life-threatening haemorrhage., PMID:36632350

Safety of direct oral anticoagulants in patients with advanced solid tumors receiving anti-VEGF agents: a retrospective study., PMID:36525139

Trends and recent developments in pharmacotherapy of acute pancreatitis., PMID:36305300

Dabigatran in the treatment and secondary prophylaxis of venous thromboembolism in children with thrombophilia., PMID:36150047

Ameliorative Effect of Dabigatran on CFA-Induced Rheumatoid Arthritis via Modulating Kallikrein-Kinin System in Rats., PMID:36142208

Comparing the efficacy and safety of direct oral anticoagulants versus Vitamin K antagonists in patients with antiphospholipid syndrome: a systematic review and meta-analysis., PMID:35867933

Costs and Healthcare Resource Utilization Associated with Idarucizumab or Andexanet Alfa Oral Anticoagulant Reversal in Patients Hospitalized with Life-Threatening Bleeds., PMID:35792949

Effectiveness and Safety of Idarucizumab for Periprocedural Cardiac Tamponade After Catheter Ablation of Atrial Fibrillation in Dabigatran Recipients: A Retrospective Controlled Study., PMID:35717554

Treatment strategy of dabigatran etexilate following the availability of idarucizumab in Japanese patients with non-valvular atrial fibrillation: J-Dabigatran Surveillance 2., PMID:35717283

No Time to Lose: Cases of Anticoagulant Reversal Before Thrombolysis in Acute Ischemic Stroke Patients., PMID:35198313

Dual-target synergistic antithrombotic mechanism of a dabigatran etexilate analogue (HY023016)., PMID:35147244

Antiphospholipid Syndrome Diagnosed as a Result of the Occurrence of an Ischemic Stroke After a Successful Catheter Ablation of Atrial Fibrillation and Continuous Direct Oral Anticoagulants., PMID:35095064

Simultaneous subacute interstitial nephritis and anticoagulant-related nephropathy related to novel oral anticoagulants use., PMID:35086437

Evaluation of the Determination of Dabigatran, Rivaroxaban, and Apixaban in Lupus Anticoagulant-Positive Patients., PMID:34829374

Retrospective Analysis of the Effectiveness of a Reduced Dose of Idarucizumab in Dabigatran Reversal., PMID:34814227

IgG4-related pachymeningitis and mastoiditis, associated with cerebral venous thrombosis: A case report., PMID:34517153

A strategy of idarucizumab for pericardial tamponade during perioperative period of atrial fibrillation ablation., PMID:34427332

Use of Direct Oral Anticoagulants in Patients With Antiphospholipid Syndrome: A Systematic Review and Comparison of the International Guidelines., PMID:34414220

Safety of idarucizumab in the reversal of dabigatran at six tertiary care Ontario hospitals., PMID:34401639

Kidney dysfunction has a major impact on the effect of idarucizumab for dabigatran reversal., PMID:34397529

ChAdOx1 nCOV-19 vaccine-induced immune thrombotic thrombocytopenia and cerebral venous sinus thrombosis (CVST)., PMID:34135077

Impact of a commercially available DOAC absorbent on two integrated procedures for lupus anticoagulant detection., PMID:34126321

A case of a markedly elevated dabigatran concentration resistant to the approved dose of idarucizumab., PMID:33890363

Heparin-induced thrombocytopenia: pathophysiology, diagnosis and treatment., PMID:33736552

DOAC-Stop in lupus anticoagulant testing: Direct oral anticoagulant interference removed in most samples., PMID:33733031

The in vitro addition of idarucizumab to plasma samples from patients increases thrombin generation., PMID:33723299

Appropriate Use of Idarucizumab for Dabigatran Reversal According to the International Society on Thrombosis and Hemostasis and French Working Group on Perioperative Hemostasis: A French Retrospective Study., PMID:33715947

Document Download

Anti-Dabigatran Etexilate Antibody (SAA0560).pdf